首页> 外文期刊>British Journal of Radiology >Radiographic contrast media induced nephropathy: experimental observations and the protective effect of calcium channel blockers.
【24h】

Radiographic contrast media induced nephropathy: experimental observations and the protective effect of calcium channel blockers.

机译:放射线造影剂诱发的肾病:实验观察和钙通道阻滞剂的保护作用。

获取原文
获取原文并翻译 | 示例
           

摘要

Combined acute inhibition of the synthesis of nitric oxide with L-nitroarginine methyl ester (L-NAME) and of prostacycline synthesis with indomethacin predisposes rats to severe renal injury from radiographic contrast media. The reliability of this pharmacological manipulation in the study of radiographic contrast medium induced nephropathy (RCMN) was investigated. Adult male Sprague-Dawley rats were injected with iv L-NAME (10 mg kg(-1)) and iv indomethacin (10 mg kg(-1)) 15 min apart and prior to injection of RCM or normal saline (control group). A dose-dependent reduction in renal function was observed after intravascular injection of the high osmolar RCM diatrizoate (Angiografin, 306 mgI ml(-1)). A significant (p<0.01) increase in serum creatinine (Cr) (from 54.66+/-8.39 micromol l(-1) to 171.96+/-24.49 micromol l(-1) and from 80.95+/-6.73 micromol l(-1) to 204.76+/-16.73 micromol (-1), n=5 per group) was observed 24 h after injection of 6 ml and 8 ml of diatrizoate, respectively. The increase in serum Cr after injection of 8 ml of diatrizoate recovered spontaneously to 80.87+/-8.70 micromol l(-1) 7 days after injection. No significant change in renal function was observed in the control group (n=5) receiving 8 ml kg(-1) of normal saline or after injection of 4 ml of diatrizoate (serum Cr 69.84+/-5.5 micromol l(-1) pre contrast injection and 66.67+/-13.47 micromol l(-1) 24 h post contrast injection, n=5). The increase in serum Cr observed with 6 ml of diatrizoate was significantly higher (p<0.01) than the rise induced by equivolume of the low osmolar non-ionic monomer iopromide (Ultravist, 300 mgI ml(-1)) (serum CR 68.47+/-8.39 micromol l(-1) pre contrast injection and 143.59+/-32.03 micromol l(-1) 24 h post contrast injection, n=5). The calcium channel blocker diltiazem (10 mg kg(-1) injected intraperitoneally 30 min prior to RCM injection) prevented the rise in serum Cr observed with 6 ml of diatrizoate (serum Cr pre contrast injection 70.31+/-7.28 micromol(-1) and 78.21+/-17.81 micromol(-1) 24 h post contrast injection in animals pre-treated with diltiazem, n=5). The protective effect against RCM-induced reduction in renal function was less with lower doses of diltiazem. In conclusion, the animal model used is reliable and reproduced previously established observations in the field of RCMN. The protective effect of a calcium channel blocker at the appropriate dose against RCMN has also been shown. The clinical effectiveness of this class of drugs in preventing RCMN requires further evaluation.
机译:L-硝基精氨酸甲酯(L-NAME)对一氧化氮合成的急性抑制作用以及吲哚美辛对前列环素合成的急性抑制作用使大鼠容易受到射线照相造影剂的严重肾损害。研究了这种药理学操作在放射线造影剂诱发的肾病(RCMN)研究中的可靠性。成年雄性Sprague-Dawley大鼠在注射RCM或生理盐水之前(对照组)分别在15分钟内注射iv L-NAME(10 mg kg(-1))和iv吲哚美辛(10 mg kg(-1))。 。血管内注射高渗RCM泛影酸盐(Angiografin,306 mgI ml(-1))后,观察到肾功能的剂量依赖性降低。血清肌酐(Cr)显着(p <0.01)增加(从54.66 +/- 8.39 micromol l(-1)增至171.96 +/- 24.49 micromol l(-1)和80.95 +/- 6.73 micromol l(- 1)分别在注射6 ml和8 ml的泛影酸盐24小时后观察到204.76 +/- 16.73 micromol(-1),每组n = 5)。注射8 ml的泛影酸盐后,血清Cr的增加在注射后7天自然恢复至80.87 +/- 8.70 micromol l(-1)。对照组(n = 5)接受8 ml kg(-1)生理盐水或注射4 ml泛影酸盐(血清Cr 69.84 +/- 5.5 micromol l(-1)后,肾功能未见明显变化。造影剂注射前和造影剂注射后24小时66.67 +/- 13.47 micromol l(-1),n = 5)。用6 ml的泛影酸盐观察到的血清Cr的增加显着高于(p <0.01)(由等渗的低渗透压的非离子单体碘普罗胺(Ultravist,300 mgI ml(-1))引起的升高(血清CR 68.47+造影剂注射前为/-8.39 micromol l(-1),造影剂注射后24 h为143.59 +/- 32.03 micromol l(-1),n = 5)。钙通道阻滞剂地尔硫卓(RCM注射前30分钟腹膜内注射10 mg kg(-1))预防了6 ml的泛影酸盐(血清Cr对比造影剂70.31 +/- 7.28 micromol(-1)观察到的血清Cr升高。在地尔硫卓预处理的动物中,造影剂注射后24小时和78.21 +/- 17.81 micromol(-1)(n = 5)。较低的地尔硫卓剂量对RCM引起的肾功能降低的保护作用较小。总之,所使用的动物模型是可靠的,并且可以复制RCMN领域先前建立的观察结果。还显示了适当剂量的钙通道阻滞剂对RCMN的保护作用。这类药物在预防RCMN中的临床有效性需要进一步评估。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号